MAMichael J. Allen

Michael J. Allen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael J. Allen has a total of 87 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Figures S1-S2 from hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma

    by Sheron Perera, Gun Ho Jang, Yifan Wang, Deirdre Kelly, Michael Allen, Amy Zhang, Robert E. Denroche, Anna Dodd, Stephanie Ramotar, Shawn Hutchinson, et al.

    Figure S1. hENT1 expression by modified Moffitt subtypes Figure S2. OS in GnP cohort stratified by hENT1 and modified Moffitt Classifier

  • Open Access

    Treatment and Survival for Unresectable Pancreatic Adenocarcinoma in Queensland, Australia, 2018–2022

    by Danny R. Youlden, Bryan A. Chan, Jon Clark, Victoria K. Donoghue, Michael J. Allen

    Background: The three main chemotherapy regimens for people with unresectable pancreatic cancer include modified FOLFIRINOX (comprising oxaliplatin, irinotecan and fluorouracil, denoted mFFX), gemcitabine with nab‐paclitaxel (GnP), and single‐agent gemcitabine (GEM). We explored characteristics associated with the type of chemotherapy and variations in survival. Materials and Methods: Records for people with unresected pancreatic adenocarcinoma between 2018 and 2022 treated with first‐line mFFX, GnP or GEM were extracted from the population‐based Queensland Oncology Repository. Multivariable Poisson models were fitted to determine factors associated with each type of chemotherapy, expressed as relative likelihoods (RLs). Variations in three‐year observed survival were assessed using flexible parametric modelling and reported in terms of adjusted excess mortality hazard ratios (HRs). Results: Of the 766 people in the study cohort, 59% were treated with GnP, 27% with mFFX, and 15% with GEM. After adjustment, treatment with mFFX was far more likely in selected private facilities compared to public hospitals (RL = 2.33, 95% CI 1.84–2.96), whereas the GEM regimen was used more often for those from outer regional/remote areas (RL = 2.20 compared to people living in major cities, 95% CI 1.45–3.34; p < 0.001). Three‐year survival was very poor at just 5% (95% CI 3%–7%). Nonetheless, adjusted mortality was higher for GnP (HR = 1.30, 95% CI 1.07–1.59) and GEM (HR = 1.53, 95% CI 1.17–2.01) compared to mFFX. Conclusions: Apart from clinical indications, there should be equity in the treatment received for unresectable pancreatic cancer. Our results suggest, however, that where a person lives and the type of facility at which they are treated may influence their chemotherapy regimen.

  • Open Access

    Outcomes in older adults with metastatic esophageal and gastric carcinoma treated with palliative chemotherapy

    by Xin Wang, Michael J Allen, Osvaldo Espin-Garcia, Chihiro Suzuiki, Yvonne Bach, Elan Panov, Lucy X Ma, Raymond W Jang, Eric X Chen, Gail E Darling, et al.

    The incidence of esophageal and gastric carcinoma (GEC) in elderly patients is increasing, yet patients ≥75 years have historically been underrepresented in clinical trials. We sought to investigate palliative chemotherapy administration patterns and survival outcomes in older adults. A retrospective analysis identified patients aged 65-74 (young-old) and ≥75 years (older-old) diagnosed with advanced GEC. Patient and tumor characteristics were recorded, with descriptive analysis, time-to-event data analysis using Kaplan-Meier curves and multivariate Cox proportional hazards regression analysis performed. One hundred and ninety-eight “young-old” and 109 ‘older-old’ patients were identified. Patient characteristics were similar between groups except for Charlson Co-morbidity Index (CCI), with lower co-morbidities in the “young-old” compared to “older-old” cohort (P < .001; CCI = 0 in 103 (52%) “young-old” vs 31 (28%) “older-old”). The primary diagnosis in both groups was adenocarcinoma. 119 (60%) “young-old” and 25 (23%) “older-old” patients received chemotherapy (P < .001). Performance status was the primary explanation for chemotherapy non-receipt in both cohorts; age was the explanation in 21 (25%) “older-old” patients and none in the “young-old” patients. PFS for first-line systemic therapy in “young-old” patients was 6.4 (95% CI 5.9-7.6) versus 7.5 months (95% CI 5.1-11.3) in “older-old” patients (P = .69) whilst respective OS was 12.3 (95% CI 10.1-15.5) and 10.4 months (95% CI 9.0-14.6) (P = .0816). Toxicity prompted chemotherapy cessation in 17 (15%) “young-old” and 3 (13%) “older-old” patients (P = .97). Multivariate analysis identified CCI and ECOG performance status as predictive for PFS and OS, respectively. No causative relationship was identified with other variables. Our study of real-world older-adults show that significant number of “older-old” patients with GEC do not receive chemotherapy. Among “older-old” adults who do receive systemic therapy, outcomes are comparable; this underscores the importance of geriatric assessment-guided care and suggests that age alone should not be a barrier to receipt of chemotherapy in patients with advanced GEC.


  • Open Access

    Supplementary Figures S1-S2 from hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma

    by Sheron Perera, Gun Ho Jang, Yifan Wang, Deirdre Kelly, Michael Allen, Amy Zhang, Robert E. Denroche, Anna Dodd, Stephanie Ramotar, Shawn Hutchinson, et al.

    Figure S1. hENT1 expression by modified Moffitt subtypes Figure S2. OS in GnP cohort stratified by hENT1 and modified Moffitt Classifier

  • Open Access

    Data from hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma

    by Sheron Perera, Gun Ho Jang, Yifan Wang, Deirdre Kelly, Michael Allen, Amy Zhang, Robert E. Denroche, Anna Dodd, Stephanie Ramotar, Shawn Hutchinson, et al.

    Purpose:Modified FOLFIRINOX (mFFX) and gemcitabine/nab-paclitaxel (GnP) remain standard first-line options for patients with advanced pancreatic ductal adenocarcinoma (PDAC). Human equilibrative nucleoside transporter 1 (hENT1) was hypothesized to be a biomarker of gemcitabine in the adjuvant setting, with conflicting results. In this study, we explore hENT1 mRNA expression as a predictive biomarker in advanced PDAC.Experimental Design:COMPASS was a prospective observational trial of patients with advanced PDAC. A biopsy was required prior to initiating chemotherapy, as determined by treating physician. Biopsies underwent laser capture microdissection prior to whole genome and RNA sequencing. The cut-off thresholds for hENT1 expression were determined using the maximal χ2 statistic.Results:253 patients were included in the analyses with a median follow-up of 32 months, with 138 patients receiving mFFX and 92 receiving GnP. In the intention to treat population, median overall survival (OS) was 10.0 months in hENT1high versus 7.9 months in hENT1low (P = 0.02). In patients receiving mFFX, there was no difference in overall response rate (ORR; 35% vs. 28%, P = 0.56) or median OS (10.6 vs. 10.5 months, P = 0.45). However, in patients treated with GnP, the ORR was significantly higher in hENT1high compared with hENT1low tumors (43% vs. 21%, P = 0.038). Median OS in this GnP-treated cohort was 10.6 months in hENT1high versus 6.7 months hENT1low (P < 0.001). In an interaction analysis, hENT1 was predictive of treatment response to GnP (interaction P = 0.002).Conclusions:In advanced PDAC, hENT1 mRNA expression predicts ORR and OS in patients receiving GnP.

  • Open Access

    Data from hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma

    by Sheron Perera, Gun Ho Jang, Yifan Wang, Deirdre Kelly, Michael Allen, Amy Zhang, Robert E. Denroche, Anna Dodd, Stephanie Ramotar, Shawn Hutchinson, et al.

    Purpose:Modified FOLFIRINOX (mFFX) and gemcitabine/nab-paclitaxel (GnP) remain standard first-line options for patients with advanced pancreatic ductal adenocarcinoma (PDAC). Human equilibrative nucleoside transporter 1 (hENT1) was hypothesized to be a biomarker of gemcitabine in the adjuvant setting, with conflicting results. In this study, we explore hENT1 mRNA expression as a predictive biomarker in advanced PDAC.Experimental Design:COMPASS was a prospective observational trial of patients with advanced PDAC. A biopsy was required prior to initiating chemotherapy, as determined by treating physician. Biopsies underwent laser capture microdissection prior to whole genome and RNA sequencing. The cut-off thresholds for hENT1 expression were determined using the maximal χ2 statistic.Results:253 patients were included in the analyses with a median follow-up of 32 months, with 138 patients receiving mFFX and 92 receiving GnP. In the intention to treat population, median overall survival (OS) was 10.0 months in hENT1high versus 7.9 months in hENT1low (P = 0.02). In patients receiving mFFX, there was no difference in overall response rate (ORR; 35% vs. 28%, P = 0.56) or median OS (10.6 vs. 10.5 months, P = 0.45). However, in patients treated with GnP, the ORR was significantly higher in hENT1high compared with hENT1low tumors (43% vs. 21%, P = 0.038). Median OS in this GnP-treated cohort was 10.6 months in hENT1high versus 6.7 months hENT1low (P < 0.001). In an interaction analysis, hENT1 was predictive of treatment response to GnP (interaction P = 0.002).Conclusions:In advanced PDAC, hENT1 mRNA expression predicts ORR and OS in patients receiving GnP.

  • Open Access

    Supplementary Figures S1-S2 from hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma

    by Sheron Perera, Gun Ho Jang, Yifan Wang, Deirdre Kelly, Michael Allen, Amy Zhang, Robert E. Denroche, Anna Dodd, Stephanie Ramotar, Shawn Hutchinson, et al.

    Figure S1. hENT1 expression by modified Moffitt subtypes Figure S2. OS in GnP cohort stratified by hENT1 and modified Moffitt Classifier

  • hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma

    by Sheron Perera, Gun Ho Jang, Yifan Wang, Deirdre Kelly, Michael Allen, Amy Zhang, Robert E. Denroche, Anna Dodd, Stephanie Ramotar, Shawn Hutchinson, et al.

    Purpose: Modified FOLFIRINOX (mFFX) and gemcitabine/nab-paclitaxel (GnP) remain standard first-line options for patients with advanced pancreatic ductal adenocarcinoma (PDAC). Human equilibrative nucleoside transporter 1 (hENT1) was hypothesized to be a biomarker of gemcitabine in the adjuvant setting, with conflicting results. In this study, we explore hENT1 mRNA expression as a predictive biomarker in advanced PDAC. Experimental Design: COMPASS was a prospective observational trial of patients with advanced PDAC. A biopsy was required prior to initiating chemotherapy, as determined by treating physician. Biopsies underwent laser capture microdissection prior to whole genome and RNA sequencing. The cut-off thresholds for hENT1 expression were determined using the maximal χ2 statistic. Results: 253 patients were included in the analyses with a median follow-up of 32 months, with 138 patients receiving mFFX and 92 receiving GnP. In the intention to treat population, median overall survival (OS) was 10.0 months in hENT1high versus 7.9 months in hENT1low (P = 0.02). In patients receiving mFFX, there was no difference in overall response rate (ORR; 35% vs. 28%, P = 0.56) or median OS (10.6 vs. 10.5 months, P = 0.45). However, in patients treated with GnP, the ORR was significantly higher in hENT1high compared with hENT1low tumors (43% vs. 21%, P = 0.038). Median OS in this GnP-treated cohort was 10.6 months in hENT1high versus 6.7 months hENT1low (P < 0.001). In an interaction analysis, hENT1 was predictive of treatment response to GnP (interaction P = 0.002). Conclusions: In advanced PDAC, hENT1 mRNA expression predicts ORR and OS in patients receiving GnP.


  • Open Access

    Preoperative and Postoperative Approaches to Gastroesophageal Cancer: What is All the Fuss About

    by Lucy X. Ma, Elan D. Panov, Michael J. Allen, Gail E. Darling, Jonathan C. Yeung, Carol J. Swallow, Savtaj S. Brar, Rebecca K. Wong, Patrick Veit-Haibach, Sangeetha N. Kalimuthu, et al.

    Gastroesophageal cancers carry poor prognoses, and are a leading cause of cancer-related morbidity and mortality worldwide. Even in those with resectable disease, more than half of patients treated with surgery alone experience disease recurrence. Multimodality approaches using preoperative and postoperative chemotherapy and/or radiotherapy have been established, resulting in incremental improvements in outcomes. Globally, there is no standardized approach, and treatment varies with geographic location. The question remains of how to select the optimal perioperative treatment that will maximize benefit for patients while avoiding toxicities from unnecessary therapies. This article reviews currently available evidence supporting preoperative and postoperative therapy in gastroesophageal cancers, with an emphasis on recent practice-changing trials and ongoing areas of investigation, including the role of immune checkpoint inhibition and biomarker-guided treatment.


  • Molecular characterisation of pancreatic ductal adenocarcinoma withNTRKfusions and review of the literature

    by Michael J Allen, Amy Zhang, Prashant Bavi, Jaeseung C Kim, Gun Ho Jang, Deirdre Kelly, Sheron Perera, Rob E Denroche, Faiyaz Notta, Julie M Wilson, et al.

    Aims: The majority of pancreatic ductal adenocarcinomas (PDACs) harbour oncogenic mutations inKRASwith variants inTP53,CDKN2AandSMAD4also prevalent. The presence of oncogenic fusions includingNTRKfusions are rare but important to identify. Here we ascertain the prevalence ofNTRKfusions and document their genomic characteristics in a large series of PDAC.Methods: Whole genome sequencing and RNAseq were performed on a series of patients with resected or locally advanced/metastatic PDAC collected between 2008 and 2020 at a single institution. A subset of specimens underwent immunohistochemistry (IHC) analysis. Clinical and molecular characterisation and IHC sensitivity and specificity were evaluated.Results: 400 patients were included (resected n=167; locally advanced/metastatic n=233). Three patients were identified as harbouring anNTRKfusion, twoEML4-NTRK3(KRAS-WT) and a single novelKANK1-NTRK3fusion. The latter occurring in the presence of a subclonalKRASmutation. Typical PDAC drivers were present including mutations inTP53andCDKN2A. Substitution base signatures and tumour mutational burden were similar to typical PDAC. The prevalence ofNTRKfusions was 0.8% (3/400), while inKRASwild-type tumours, it was 6.25% (2/32). DNA prediction alone documented six false-positive cases. RNA analysis correctly identified the in-frame fusion transcripts. IHC analysis was negative in theKANK1-NTRK3fusion but positive in aEML4-NTRK3case, highlighting lower sensitivity of IHC.Conclusion: NTRKfusions are rare; however, with emerging therapeutic options targeting these fusions, detection is vital. Reflex testing forKRASmutations and subsequent RNA-based screening could help identify these cases in PDAC.